Calendrier des promotions MediciNova, Inc.
Calendrier avancé
Graphique simple
À propos de l'entreprise MediciNova, Inc.
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.Paramètres de base
IPO date
2005-02-08
ISIN
US58468P2065
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
Grade
Sous-estimation
Nom | Signification | Grade |
P/S | 71.61 | 1 |
P/BV | 1.97 | 7 |
P/E | 0 | 0 |
Efficacité
Nom | Signification | Grade |
ROA | -18.09 | 0 |
ROE | -19.24 | 0 |
ROIC | 0 | 0 |
Dividendes
Nom | Signification | Grade |
Rendement en dividendes | 0 | 0 |
DSI | 0 | 0 |
Croissance moyenne du dividende | 0 | 0 |
Devoir
Nom | Signification | Grade |
Debt/EBITDA | -0.0196 | 10 |
Debt/Ratio | 0.0035 | 10 |
Debt/Equity | 0.0642 | 10 |
Impulsion de croissance
Nom | Signification | Grade |
Rentabilité Revenue, % | 24.6 | 4 |
Rentabilité Ebitda, % | -29.43 | 0 |
Rentabilité EPS, % | -27.77 | 0 |
paper.price.prices
Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
common.calendar.number_days.1 | 1.33 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
common.calendar.number_days.7d | 1.36 $ | 0 $ | 0 $ | -2.21 % | 0 % | 0 % |
common.calendar.number_days.30d | 1.41 $ | 1.33 $ | 1.38 $ | -5.67 % | 0 % | 0 % |
common.calendar.number_days.90d | 1.38 $ | 1.32 $ | 1.59 $ | -3.62 % | 0 % | 0 % |
common.calendar.number_days.180d | 1.87 $ | 1.2 $ | 2.05 $ | -28.88 % | 0 % | 0 % |
common.calendar.number_days.1y | 1.37 $ | 1.13 $ | 2.38 $ | -2.92 % | 0 % | 0 % |
common.calendar.number_days.3y | 2.17 $ | 1.13 $ | 2.66 $ | -38.71 % | 0 % | 0 % |
common.calendar.number_days.5y | 6.26 $ | 1.13 $ | 11 $ | -78.75 % | 0 % | 0 % |
common.calendar.number_days.10y | 1.13 $ | 1.13 $ | 13.91 $ | 117.7 % | 0 % | 0 % |
common.calendar.number_days.ytd | 2.05 $ | 1.2 $ | 2.16 $ | -35.12 % | 0 % | 0 % |
Principaux propriétaires
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
Superviseur | Titre d'emploi | Paiement | Année de naissance |
Dr. Yuichi Iwaki M.D., Ph.D. | Co-Founder, President, CEO & Executive Director | 907.26k | 1950 (75 années) |
Dr. Kazuko Matsuda M.D., M.P.H., Ph.D. | Chief Medical Officer & Director | 649.05k | 1966 (59 années) |
Mr. Jason J. Kruger CPA | CFO & Principal Financial Officer | N/A | 1978 (47 années) |
Dr. David H. Crean M.B.A., Ph.D. | Chief Business Officer | N/A | 1965 (60 années) |
Mr. John O'Neil CPA | Controller |
Informations sur l'entreprise
Adresse: United States, La Jolla. CA, 4275 Executive Square - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.medicinova.com
Site web: https://www.medicinova.com